KR100598309B1 - 세포 이동성 검사 - Google Patents
세포 이동성 검사 Download PDFInfo
- Publication number
- KR100598309B1 KR100598309B1 KR1020037015768A KR20037015768A KR100598309B1 KR 100598309 B1 KR100598309 B1 KR 100598309B1 KR 1020037015768 A KR1020037015768 A KR 1020037015768A KR 20037015768 A KR20037015768 A KR 20037015768A KR 100598309 B1 KR100598309 B1 KR 100598309B1
- Authority
- KR
- South Korea
- Prior art keywords
- cell migration
- chemokine
- ligand
- receptor
- antagonist
- Prior art date
Links
- 0 CC(**CC=C)C=CC=C(*(C)=C)N1CC1 Chemical compound CC(**CC=C)C=CC=C(*(C)=C)N1CC1 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
- Spectrometry And Color Measurement (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (22)
- 화학주성인자 수용체 길항제를 확인하는 방법에 있어서, 아래의 단계로 구성되는 것을 특징으로 하는 방법:화학주성인자 수용체를 포함하는 세포를 후보 길항제와 함께 배양하고;화학주성인자 수용체에 대한 세포 이동 저해 농도의 리간드를 상기 세포에 접촉시키고;세포 이동을 검사하고, 여기서 세포 이동은 후보 길항제가 길항제임을 확인시킨다.
- 제 1항에 있어서, 후보 길항제는 소형 펩티드, 펩티드-유사 분자, 비-펩티드성 유기 화합물, 무기 화합물, 핵산 또는 항체인 것을 특징으로 하는 방법.
- 제 1항에 있어서, 화학주성인자 수용체에 대한 세포 이동 저해 농도의 리간드는 리간드-활성화된 최대 세포 이동의 50% 이상 수준까지 세포 이동을 저해하는 것을 특징으로 하는 방법.
- 제 1항에 있어서, 화학주성인자 수용체에 대한 세포 이동 저해 농도의 리간드는 리간드-활성화된 최대 세포 이동의 95% 이상 수준까지 세포 이동을 저해하는 것을 특징으로 하는 방법.
- 제 1항에 있어서, 화학주성인자 수용체에 대한 세포 이동 저해 농도의 리간드는 리간드-활성화된 최대 세포 이동의 100% 수준까지 세포 이동을 저해하는 것을 특징으로 하는 방법.
- 제 1항에 있어서, 화학주성인자 수용체는 FPRL1 수용체로 구성되고, 화학주성인자는 FPRL1에 대한 리간드로 구성되는 것을 특징으로 하는 방법.
- 제 6항에 있어서, FPRL1에 대한 리간드는 w-peptidel과 w-peptide2에서 선택되는 것을 특징으로 하는 방법.
- 케모킨 수용체 길항제를 확인하는 방법에 있어서, 아래의 단계로 구성되는 것을 특징으로 하는 방법:케모킨 수용체를 포함하는 세포를 후보 길항제와 함께 배양하고;케모킨 수용체에 대한 세포 이동 저해 농도의 리간드를 상기 세포에 접촉시키고;세포 이동을 검사하고, 여기서 세포 이동은 후보 길항제가 길항제임을 확인시킨다.
- 제 8항에 있어서, 후보 길항제는 소형 펩티드, 펩티드-유사 분자, 비-펩티드성 유기 화합물, 무기 화합물, 핵산 또는 항체인 것을 특징으로 하는 방법.
- 제 8항에 있어서, 케모킨 수용체는 CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CCR11, CX3CR1 또는 XCR1인 것을 특징으로 하는 방법.
- 제 8항에 있어서, 케모킨은 CCR, CXCR, CX3CR 리간드에서 선택되는 것을 특징으로 하는 방법.
- 제 11항에 있어서, 케모킨은 IL-8, GCP-2, Gro α, Gro β, Gro γ, ENA-78, PBP, MIG, IP-10, I-TAC, SDF-1, BLC, MIP-1α, MIP-1β, RANTES, HCC-1, HCC-2, HCC-3, HCC-4, MCP-1, MCP-2, MCP-3, MCP-4, 이오탁신(eotaxin)-1, 이오탁신(eotaxin)-2, TARC, MDC, MIP-3α, MIP-3β, 6Ckine, I-309, TECK, 임포택틴, 프랙트알킨, TCA-4, Exodus-2, Exodus-3 또는 CKβ-11인 것을 특징으로 하는 방법.
- 제 8항에 있어서, 케모킨 수용체는 CCR5로 구성되고, 케모킨은 MIP-1α, MIP-1β 또는 RANTES로 구성되는 것을 특징으로 하는 방법.
- 제 8항에 있어서, 케모킨 수용체는 CXCR4로 구성되고, 케모킨은 SDF-1로 구성되는 것을 특징으로 하는 방법.
- 제 8항에 있어서, 케모킨 수용체는 CCR9로 구성되고, 케모킨은 TECK로 구성되는 것을 특징으로 하는 방법.
- 제 8항에 있어서, 케모킨 수용체는 CCR10으로 구성되고, 케모킨은 CTACK로 구성되는 것을 특징으로 하는 방법.
- 제 8항에 있어서, 케모킨 수용체에 대한 세포 이동 저해 농도의 리간드는 리간드-활성화된 최대 세포 이동의 50% 이상 수준까지 세포 이동을 저해하는 것을 특징으로 하는 방법.
- 제 8 항에 있어서, 케모킨 수용체에 대한 세포 이동 저해 농도의 리간드는 리간드-활성화된 최대 세포 이동의 95% 이상 수준까지 세포 이동을 저해하는 것을 특징으로 하는 방법.
- 제 8항에 있어서, 케모킨 수용체에 대한 세포 이동 저해 농도의 리간드는 리간드-활성화된 최대 세포 이동의 100% 수준까지 세포 이동을 저해하는 것을 특징으로 하는 방법.
- 삭제
- 삭제
- 케모킨 수용체 길항제를 확인하는 방법에 있어서, 아래의 단계로 구성되는 것을 특징으로 하는 방법:화학주성인자 수용체에 대한 리간드를 포함하는 이동 검사에서 케모킨 수용체의 후보 길항제를 확인하고;케모킨 수용체를 포함하는 세포를 상기 후보 길항제와 함께 배양하고;케모킨 수용체에 대한 세포 이동 저해 농도의 리간드를 세포에 접촉시키고;세포 이동을 검사하고, 여기서 세포 이동은 후보 길항제가 길항제임을 확인시킨다.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29668201P | 2001-06-07 | 2001-06-07 | |
US60/296,682 | 2001-06-07 | ||
US10/154,399 US7282338B2 (en) | 2001-06-07 | 2002-05-22 | Cell migration assay |
PCT/US2002/016325 WO2002101350A2 (en) | 2001-06-07 | 2002-05-22 | Cell migration assay |
US10/154,399 | 2002-05-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067007834A Division KR100635703B1 (ko) | 2001-06-07 | 2002-05-22 | 세포 이동성 검사 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040012888A KR20040012888A (ko) | 2004-02-11 |
KR100598309B1 true KR100598309B1 (ko) | 2006-07-10 |
Family
ID=26851415
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037015768A KR100598309B1 (ko) | 2001-06-07 | 2002-05-22 | 세포 이동성 검사 |
KR1020067007834A KR100635703B1 (ko) | 2001-06-07 | 2002-05-22 | 세포 이동성 검사 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067007834A KR100635703B1 (ko) | 2001-06-07 | 2002-05-22 | 세포 이동성 검사 |
Country Status (11)
Country | Link |
---|---|
US (3) | US7282338B2 (ko) |
EP (2) | EP1417488B1 (ko) |
JP (2) | JP4233092B2 (ko) |
KR (2) | KR100598309B1 (ko) |
AT (1) | ATE347695T1 (ko) |
CA (1) | CA2449628C (ko) |
DE (1) | DE60216606T2 (ko) |
DK (1) | DK1417488T3 (ko) |
ES (1) | ES2274041T3 (ko) |
HK (1) | HK1065844A1 (ko) |
WO (1) | WO2002101350A2 (ko) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1417488B1 (en) * | 2001-06-07 | 2006-12-06 | ChemoCentryx Inc | Cell migration assay |
AU2003267088A1 (en) * | 2002-09-11 | 2004-04-30 | Medical College Of Georgia Research Institute, Inc. | Chemokine receptor antagonists as therapeutic agents |
US7919083B2 (en) * | 2002-11-15 | 2011-04-05 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
EP1798223B2 (en) | 2002-11-18 | 2014-07-30 | ChemoCentryx, Inc. | Aryl sulfonamides |
KR20060114381A (ko) * | 2004-02-13 | 2006-11-06 | 레프로셀 인코퍼레이티드 | 배아줄기세포용 피더세포 작성 배지 및 피더세포 |
US20060173019A1 (en) | 2005-01-14 | 2006-08-03 | Solomon Ungashe | Heteroaryl sulfonamides and CCR2 |
US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
NZ574759A (en) | 2006-07-14 | 2010-10-29 | Chemocentryx Inc | Triazolyl phenyl benzenesulfonamides |
US8519135B2 (en) | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
DK2041282T3 (en) * | 2006-07-18 | 2018-04-16 | Noxxon Pharma Ag | SDF-I-binding nucleic acids |
WO2009009740A1 (en) | 2007-07-12 | 2009-01-15 | Chemocentryx, Inc. | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treament of inflammation |
WO2009019007A2 (en) | 2007-08-06 | 2009-02-12 | Noxxon Pharma Ag | Sdf-1 binding nucleic acids and the use thereof |
CA2810950C (en) | 2010-09-09 | 2023-02-14 | Noxxon Pharma Ag | Sdf-1 binding nucleic acids and the use thereof in cancer treatment |
AU2011329647B2 (en) | 2010-11-19 | 2015-10-22 | Eisai R&D Management Co., Ltd. | Neutralizing anti-CCL20 antibodies |
CN104849377A (zh) * | 2015-01-29 | 2015-08-19 | 衢州市质量技术监督检测中心 | 一种气质法快速测定畜禽肉中β-***的前处理方法 |
KR20190088513A (ko) | 2016-11-23 | 2019-07-26 | 케모센트릭스, 인크. | 국소 분절 사구체경화증의 치료 방법 |
JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
SG11202002975YA (en) | 2017-10-11 | 2020-04-29 | Chemocentryx Inc | Treatment of focal segmental glomerulosclerosis with ccr2 antagonists |
WO2022023956A1 (en) | 2020-07-31 | 2022-02-03 | The Joan and Irwin Jacobs Technion-Cornell Institute | System and method for on-phase microscopy |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5811128A (en) | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5284753A (en) | 1991-03-20 | 1994-02-08 | Neuro Probe, Inc. | Multiple-site chemotactic test apparatus and method |
SE9600820D0 (sv) * | 1996-03-01 | 1996-03-01 | Pharmacia Ab | Antibodies and their use |
US5928881A (en) * | 1996-07-11 | 1999-07-27 | Smithkline Beecham Corporation | Method of identifying agonists and antagonist for CC-CKR5 receptor |
GB9617923D0 (en) * | 1996-08-28 | 1996-10-09 | Smithkline Beecham Plc | Novel receptor |
US6153441A (en) * | 1998-02-17 | 2000-11-28 | Smithkline Beecham Corporation | Methods of screening for agonists and antagonists for human CCR7 receptor and CKβ-9 ligand and interaction thereof |
US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
US6649158B1 (en) * | 1998-10-15 | 2003-11-18 | Canji, Inc. | Methods and compositions to induce antitumor response |
WO2000031261A2 (en) | 1998-11-25 | 2000-06-02 | Cadus Pharmaceutical Corporation | Methods and compositions for identifying effectors of the formyl peptide receptor like-1 (fprl-1) receptor |
US6329159B1 (en) | 1999-03-11 | 2001-12-11 | Millennium Pharmaceuticals, Inc. | Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function |
US6448054B1 (en) * | 1999-04-08 | 2002-09-10 | The General Hospital Corporation | Purposeful movement of human migratory cells away from an agent source |
EP1417488B1 (en) * | 2001-06-07 | 2006-12-06 | ChemoCentryx Inc | Cell migration assay |
-
2002
- 2002-05-22 EP EP02739361A patent/EP1417488B1/en not_active Expired - Lifetime
- 2002-05-22 DK DK02739361T patent/DK1417488T3/da active
- 2002-05-22 WO PCT/US2002/016325 patent/WO2002101350A2/en active IP Right Grant
- 2002-05-22 JP JP2003504063A patent/JP4233092B2/ja not_active Expired - Lifetime
- 2002-05-22 US US10/154,399 patent/US7282338B2/en not_active Expired - Lifetime
- 2002-05-22 ES ES02739361T patent/ES2274041T3/es not_active Expired - Lifetime
- 2002-05-22 DE DE60216606T patent/DE60216606T2/de not_active Expired - Lifetime
- 2002-05-22 AT AT02739361T patent/ATE347695T1/de active
- 2002-05-22 KR KR1020037015768A patent/KR100598309B1/ko active IP Right Grant
- 2002-05-22 CA CA002449628A patent/CA2449628C/en not_active Expired - Lifetime
- 2002-05-22 EP EP06017100A patent/EP1717583A3/en not_active Withdrawn
- 2002-05-22 KR KR1020067007834A patent/KR100635703B1/ko active IP Right Grant
-
2004
- 2004-11-08 HK HK04108760A patent/HK1065844A1/xx not_active IP Right Cessation
-
2005
- 2005-01-24 US US11/041,858 patent/US20050186556A1/en not_active Abandoned
-
2007
- 2007-04-17 US US11/788,334 patent/US7396653B2/en not_active Expired - Lifetime
-
2008
- 2008-06-18 JP JP2008158580A patent/JP4340713B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20050186556A1 (en) | 2005-08-25 |
ES2274041T3 (es) | 2007-05-16 |
DE60216606D1 (de) | 2007-01-18 |
ATE347695T1 (de) | 2006-12-15 |
JP2009000113A (ja) | 2009-01-08 |
EP1717583A2 (en) | 2006-11-02 |
KR20040012888A (ko) | 2004-02-11 |
KR100635703B1 (ko) | 2006-10-17 |
JP4233092B2 (ja) | 2009-03-04 |
JP2005518184A (ja) | 2005-06-23 |
CA2449628A1 (en) | 2002-12-19 |
US7396653B2 (en) | 2008-07-08 |
CA2449628C (en) | 2008-05-06 |
JP4340713B2 (ja) | 2009-10-07 |
EP1417488B1 (en) | 2006-12-06 |
WO2002101350A3 (en) | 2004-03-11 |
US20030017485A1 (en) | 2003-01-23 |
DE60216606T2 (de) | 2007-04-05 |
EP1417488A2 (en) | 2004-05-12 |
EP1717583A3 (en) | 2007-10-10 |
WO2002101350A2 (en) | 2002-12-19 |
EP1417488A4 (en) | 2004-07-14 |
HK1065844A1 (en) | 2005-03-04 |
DK1417488T3 (da) | 2007-03-05 |
KR20060054488A (ko) | 2006-05-22 |
US20070196855A1 (en) | 2007-08-23 |
US7282338B2 (en) | 2007-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4340713B2 (ja) | 細胞移動の増加の測定方法 | |
Pelletier et al. | Presentation of chemokine SDF-1α by fibronectin mediates directed migration of T cells | |
US7468253B2 (en) | Method for multiple chemokine receptor screening for antagonists using RAM assay | |
Muri et al. | Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course | |
Soriano et al. | Functional inactivation of CXC chemokine receptor 4–mediated responses through SOCS3 up-regulation | |
Jin et al. | Rapid isolation of antigen-specific antibody-secreting cells using a chip-based immunospot array | |
Kim et al. | Detection of HIV-1 p24 Gag in plasma by a nanoparticle-based bio-barcode-amplification method | |
US20030022245A1 (en) | Method and compositions for analysis of pentraxin receptors as indicators of disease | |
JP2016500255A (ja) | ハイスループットなレセプター:リガンド同定の方法 | |
Ikegawa et al. | Elevated plasma stromal cell-derived factor 1 protein level in the progression of HIV type 1 infection/AIDS | |
US6858400B2 (en) | Detection of surface-associated human leukocyte elastase | |
Ford et al. | Using fluorescent chemokine uptake to detect chemokine receptors by fluorescent activated cell sorting | |
Cludts et al. | Detection of neutralizing interleukin-17 antibodies in autoimmune polyendocrinopathy syndrome-1 (APS-1) patients using a novel non-cell based electrochemiluminescence assay | |
AU2002312014A1 (en) | Cell migration assay | |
Teng et al. | Engineering binders with exceptional selectivity | |
AU2003266749C1 (en) | Method for Multiple Chemokine Receptor Screening for Antagonists Using RAM Assay | |
CA2452254C (en) | Method for multiple chemokine receptor screening for antagonists using ram assay | |
AU2006200356A1 (en) | Method for multiple chemokine receptor screening for antagonists using RAM assay | |
Kershaw et al. | Analysis of chemokine receptor endocytosis and intracellular trafficking | |
Taub et al. | Biological responses to chemokine superfamily members | |
Perry et al. | Using in vitro pull-down and in-cell overexpression assays to study protein interactions with arrestin | |
Islam et al. | Chemokine and chemokine receptor analysis | |
Blanco et al. | Multiparametric assay to screen and dissect the mode of action of anti-human immunodeficiency virus envelope drugs | |
Beck et al. | Digital Protein Detection in Bulk Solutions | |
Mack et al. | Downmodulation and recycling of chemokine receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
A107 | Divisional application of patent | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130531 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140529 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150430 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160330 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170330 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180416 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20190327 Year of fee payment: 14 |